Age-Related Changes in the Hepatic Pharmacology and Toxicology of Paracetamol by Mitchell, Sarah J. et al.
Hindawi Publishing Corporation
Current Gerontology and GeriatricsResearch
Volume 2011, Article ID 624156, 14 pages
doi:10.1155/2011/624156
Review Article
Age-Related Changesin theHepaticPharmacology and
Toxicology of Paracetamol
SarahJ.Mitchell,1,2,3,4,5 AliceE.Kane,2,3,4,5 andSarahN. Hilmer2,3,4,5
1Laboratory of Experimental Gerontology, National Institute on Aging, National Institutes of Health, Baltimore,
MD 21224-6825, USA
2Kolling Institute of Medical Research, The Royal North Shore Hospital, St. Leonards, NSW 2065, Sydney, Australia
3Department of Clinical Pharmacology, The Royal North Shore Hospital, Paciﬁc highway, St. Leonards,
NSW 2065, Sydney, Australia
4Sydney Medical School, University of Sydney, St. Leonards, NSW 2065, Sydney, Australia
5Laboratory of Ageing and Pharmacology, Level 12 Kolling Building, The Royal North Shore Hospital,
Paciﬁc Highway, St Leonards NSW 2065, Australia
Correspondence should be addressed to Sarah J. Mitchell, sarah.mitchell@sydney.edu.au
Received 31 January 2011; Accepted 29 March 2011
Academic Editor: Victoria Cogger
Copyright © 2011 Sarah J. Mitchell et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Optimal pharmacotherapy is determined when the pharmacokinetics and pharmacodynamics of the drug are understood.
However, the age-related changes in pharmacokinetics and pharmacodynamics, as well as the increased interindividual variation
mean optimal dose selection are a challenge for prescribing in older adults. Poor understanding of how hepatic clearance and
toxicity are diﬀerent with age results in suboptimal dose selection, poor eﬃcacy, and/or increased toxicity. Of particular concern
is the analgesic paracetamol which has been in use for more than 50 years and is consumed by a large proportion of older
adults. Paracetamol is considered to be a relatively safe drug; however, caution must be taken because of its potential for toxicity.
Paracetamol-induced liverinjury fromaccidental overdoseaccountsforup to55% ofcasesin olderadults. Better understanding of
how age aﬀects the hepatic clearance and toxicity of drugs will contribute to evidence-based prescribing for older people, leading
to fewer adverse drug reactions without loss of beneﬁt.
1.Introduction
Paracetamol remains one of the most studied agents that
cause hepatotoxicity due to its clinical relevance and to its
dose-dependent hepatotoxicity in animals and humans [1].
Paracetamol is an eﬀective analgesic agent and represents
the ﬁrst-line analgesic therapy for nonmalignant pain [2].
However, the use of paracetamol is limited by its potential
to cause hepatotoxicity. With old age, there is an increase in
disease for which medications may provide beneﬁt; however,
the incidence of serious adverse drug reactions (ADRs)
also increases with increasing age, even after controlling
for increased medication use [3]. In older adults, most
ADRs, including drug-induced liver injury (DILI), are dose-
related [4]. Therefore, optimising the safety and eﬃcacy of
medication use in older adults is important.
For most drugs, the evidence base for dose adjustment
in older people is limited to pharmacokinetic studies in
small populations of healthy volunteers. There is very little
data available on the clinical outcomes of dose adjustment,
particularly in the frail aged. In all age groups, an important
susceptibility factor for hepatotoxicity is genetic variability
[5]. In older people, this may be compounded by the
multi-factorial large interindividual variation in response
to medications further increasing the risks of toxicity and
poor eﬃcacy [5]. This is a particular concern in frailty, a
condition of increased vulnerability to adverse events [6].
Although monitoring for clinical response is essential to
optimise eﬃcacyand reducetoxicity,thedetectionofadverse
eﬀects of medications in older patients may be complicated
by nonspeciﬁc presentation as “geriatric syndromes” [7]. In
addition, age-related changes in the pharmacokinetics and2 Current Gerontology and Geriatrics Research
pharmacodynamics of drugs further compounds the risk
of toxicity. In older adults, the clinical increased risk of
paracetamol hepatotoxicity is likely to be related to dosing
that does not account for decreased liver volume with age,
and to frailty and malnutrition [8]. However, recent discov-
eries about the ageing liver identify novel mechanisms for
age-related changes in hepatic pharmacology and toxicology
(summarised in Figure 1). In this paper, we describe the age-
related physiologicalchanges, with particular attention to the
liver speciﬁc changes, and how they can impact on hepatic
pharmacology and toxicology of paracetamol.
2.Physiological ChangesinAgeing
The most marked pharmacologic change with ageing is
increased interindividual variation. The most signiﬁcant
pharmacokinetic change in ageing is related to the decreased
hepaticmass, uptake,andbloodﬂow[9,10]an dt odecr eas ed
renal function [11], impairing the clearance of many drugs
and their metabolites [12]. Table 1 summarises the physio-
logical changes associated with ageing and frailty that can
impact on the pharmacokinetics and pharmacodynamics of
drugs.
Changes in the pharmacodynamics of drugs in old age is
related to changes in drug receptors, physiologic reserve and
in response to injury [12]. However, these changes have not
been as well characterised in ageing as the pharmacokinetic
changes. The cardiovascular and central nervous systems
are the two best described. A reduction in the respon-
siveness of the cardiac and β-adrenergic system has been
observed in older adults [14]. In the central nervous system,
the numbers of dopaminergic neurons and dopamine D2
receptors decrease with age resulting in extrapyramidal
side eﬀects [26]. Studies in animal models suggest that
increased sensitivity to narcotic and anaesthetic agents may
be due to alteration of opioid receptors (decreased μ-
opioid receptor density and increased aﬃnity) in old age
[15].
Ageing is associated with changes in body composition,
including a reduction in total and lean body mass, and a
relative increase in fat mass [12, 27], which may aﬀect the
volume of distribution and loading dose of drugs. Sarcope-
nia, deﬁned as loss of muscle mass and strength with ageing,
increases with age and is associated with frailty [5, 27]. It
can be the result of concomitant diseases, neuroendocrine
dysregulation and/or chronic inﬂammation [27].
3.LiverSpeciﬁcChangesinAgeing
The age-related reduction in liver size is noted to be in the
order of 25 to 35%, which has been conﬁrmed in many
species including humans [9, 28–30]. The main age-related
changeinthephysiologyoftheliverisasubstantialreduction
in blood ﬂow of about 40% [29] which has been postulated
to be due to leukocyte accumulation in the sinusoids and
narrowing of sinusoidal lumens due to pseudocapillarisation
and dysfunction of the liver sinusoidal endothelial cells
(LSECs) [31].
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Figure 1: Hepatic pharmacology and toxicology in old age. (A)
Pseudocapillarisation (thickening, defenestration, and basement
membrane formation) of the liver sinusoidal endothelial cells
(LSECs) may aﬀect susceptibility to drug-induced liver injury
(DILI); (B) Changesin protein bindingin old ageaﬀect the amount
of free drug available for clearance; (C) Dysregulation of Kupﬀer
cell activation may alter inﬂammatory response to DILI; (D) Pseu-
docapillarisation of the LSECs, and any changes in transporters,
may alter drug transfer from the blood to hepatocytes; (E) Age-
related changes in hepatic metabolism aﬀect drug clearance: phase
I metabolism is reduced, and changes in phase II metabolism are
less well understood; (F) Reduced glutathione (GSH) in old age
increases injury by toxic metabolites; (G) Expression of hepatic
transporters in response to drug toxicity is poorly described in old
age and aﬀects biliary excretion of drugs and their metabolites; (H)
Changes in mitochondrial structure and function in old age alter
response to reactive oxygen species and cell death pathways. Steps
(E), (F), and (G) are regulated by nuclear factor E2-related factor
2 (Nrf-2) which has reduced hepatic expression in old age. Figure
adapted from [24, 25].
3.1. Pseudocapillarisation of the Liver Sinusoidal Endothelium.
The sinusoidal endothelium is a thin fenestrated endothe-
lium lacking a basal lamina and punctuated with fenestra-
tions of 50 to 200nm in diameter grouped together in
clusters known as liver sieve plates [32–35]. With ageing, the
LSECs undergo ultrastructural changes termed pseudocap-
illarisation [16] that include that include loss of fenestra-
tions, thickeningof the endothelium, perisinusoidal collagen
deposition, and basal lamina formation [16, 36, 37], which
may aﬀect hepatic drug disposition. Recently, the endocytic
capacity of LSECs was reported to be reduced in oldCurrent Gerontology and Geriatrics Research 3
Table 1:Physiologicalchanges associatedwithageingandfrailtythatcanimpactonthepharmacokineticsandpharmacodynamicsofdrugs.
Physiologicalchange Pharmacokineticconsequences
↑ Gastric pH Delay in absorption no change in the overall
↓ Secretory capacity extent
↓ Gastrointestinal blood ﬂow
↓ Absorption surface
↓ Gastrointestinal motility
↑ Body fat ↑ Vd and t1/2
↓ Lean body mass ↑ Plasma concentration and ↓ Vd of hydrophilic
drugs
↓ Total body water ↑ Free fraction of highly protein-bound acidic
↓ Serum albumin drugs
↑ α1-acid glycoprotein ↓ Free fraction of basic drugs
↓ Hepatic blood ﬂow ↓ First-pass metabolism
↓ Hepatic mass Phase I metabolism of some drugs may be slightly
↓ CYP content impaired
↓ / ↔ Phase II in ﬁt older adults, ↓in frail
?/ ↓ Phase III
Pseudocapillarisation of the liver Impaired transfer of chylomicrons and possibly
sinusoidal endothelium medications from sinusoid to space of Disse
↓ Renal blood ﬂow and glomerular Renal elimination of drugs can be impaired
ﬁltration rate altering drug half-life
↓ Tubular secretion
Physiological change Pharmacodynamic consequences
↓ Blood supply to brain ↑ Sensitivity to centrally acting drugs such as
↓ Baroreceptor activity benzodiazepines
↓ Resting heart rate, stroke volume, and ↓ Response to beta blockers such as metoprolol
cardiac output
↓ Plasma renin
↓ Urine aldosterone
↓ Hepatic GSH ↓ Detoxiﬁcation ability of the liver
Dysregulation of Kupﬀer cells Dysregulation of immune response to drugs and
Dysregulation of the immune system other toxins
Mitochondrial dysregulation ↑ Susceptibility to DILI
↓,decreased; ↑,in cr eased;↔,no change; ?,unknown; CYP,CytochromeP450;Vd, volumeofdistribution;t1/2, half-life;DILI, drug-induced liverinjury;GSH,
glutathione; adapted from [13] and references [2, 11–23].
age, which may be especially important in situations with
increased circulatory waste loads [38].
3.2. Dysregulation of Kupﬀer Cell Activation. Kupﬀer cells
(KCs) are the resident phagocytic macrophages in the liver,
which represent the largest population of ﬁxed macrophages
inthebodyandaccountforapproximately20%ofnonparen-
chymal cells in the liver [39]. KCs have diverse functions,
including phagocytosis, endocytosis, immuno-modulation,
and synthesis and secretion of numerous biologically active
mediators [39, 40]. Furthermore, the dual role of activated
KCs in releasing both pro- and anti-ﬂammatory mediators
during the diﬀerent stages of liver injury and regeneration
has been demonstrated [39]. It is likely that dysregulation
of the KCs with ageing may alter the inﬂammatory response
to DILI; however, there is conﬂicting evidence. For example,
while there is a basal increase in the numbers of KCs
in old rats [40] ,t h e i ra c t i v a t i o ni nr e s p o n s et ot o x i c
doses of cadmium and endotoxin is decreased [41, 42].
However, KCs in lipopolysaccharide-treated had showed no
diﬀerence in activity with the phagocytosis of ﬂuorescent
bea dsbei n gs i m i la ra cr os sa gegr oups[43].TheroleofKCsin
paracetamol-induced hepatotoxicity will be discussed below.
3.3. Age-Related Changes in Hepatic Metabolism Aﬀect Drug
Clearance. Age-related changes in hepatic metabolism will
aﬀect drug clearance and toxicity. In general, there is a
reduction in Phase I metabolism in vivo with normal ageing4 Current Gerontology and Geriatrics Research
Table 2: Changes in the cytochrome P450 activity with ageing.
CYP Enzyme Change with ageing Probe drug used Confounding factors
CYP1 ↓ Theophylline
Ethnic polymorphisms,
sex diﬀerences,
lifestyle, and disease
CYP2
CYP2C9
CYP2C19
↓ (∼25%)
Phenytoin
Warfarin
Omeprazole
Age-related eﬀects, and
unrecognised
environmental eﬀects,
and pharmacogenetic
variation
CYP2D6
↓ Older women
↓ Older Japanese men
Dextromethorphan
Haloperidol
Genetic
polymorphisms
CYP2E1
↓ Aged rats
↔ Aged mice
↓ Activity in human
liver microsomes
↔ Human hepatocytes
Chlorzoxazone ? Gender-conﬂicting
results Polymorphisms
CYP3A
CYP3A4
↓ Aged rodents
↔ Humans
↑ CL in women, no age
eﬀects
Cyclosporine,
Erythromycin,
Verapamil,
Midazolam
Inducers
Inducers
Multiple ↓ Antipyrine
Metabolised by
CYP3A4, 1A2 and
2C8/9
CYP, cytochrome P450; ↓, decreased; ↑,i n c r e a s e d ;↔, no change; ?, unknown; CL, clearance; adapted from [13, 52–55].
in the order of 30%–50% [24]. Phase II metabolism appears
to be maintained in the healthy elderly but reduced in the
frail [24]. The Phase III transporters have not been well
described in humans.
The Phase I drug metabolising enzymes (DMEs) consist
of the superfamily of CYP450 enzymes. Animal studies
have indicated that total CYP content is reduced in aged
rats [44]. In humans, it has been suggested that CYP450
content declines at a rate of 0.07nmol/g of liver after 40
years of age [45]. However, there is conﬂicting evidence on
the CYP activity with age (Table 2). For example evidence
from liver biopsies of surgical patients indicate that normal
ageing does not aﬀect the activity of human CYP2E1,
other evidence suggests that CYP2E1 activity may decrease
with age [46]. Furthermore it has been suggested that the
induction of CYP2E1 could also be aﬀected by advanced
age [47]. Interestingly it has shown that sex and concurrent
medications have a greater eﬀect than chronological age on
CYP3A substrates in older patient populations [48, 49]. Frail
older persons do not have slower erythromycin breath test
results compared with non frail older persons potentially
indicatingpreservedCYP3Aactivityaswell asP-glycoprotein
(P-gp) transport, in frailty [48].
However, it can be assumed that there is some minor
impairment in CYP activity with ageing given that there is a
small decline (in the order of 20% observed in patients aged
25–75 years) in antipyrine clearance with age and antipyrine
is metabolised by multiple CYPs [45, 50, 51]. The eﬀect of
disease, concurrentmedications and frailty, and comorbidity
on CYP activity still needs to be investigated given that these
studies were conducted in relatively healthy volunteers.
Phase II metabolism acts to increase hydrophilicity of
the compounds, and thereby enhance excretion in bile
and or urine [63]. Enzymes include the sulfotransferases,
UDP-glucuronosyltransferases (UGTs), and glutathione s-
transferases (GSTs). Most data suggest that the Phase II
conjugation pathways are not altered by ageing [13, 52].
However, a recent reanalysis of pharmacokinetic studies
in old age found that the apparent preservation of Phase
II metabolism may have been confounded by inadequate
consideration of protein binding [64]. Therefore, suggesting
that Phase II metabolism is impaired in healthy ageing [64].
This is consistent with animal studies in which transcript
proﬁles for the glucuronidation, sulfation, and glutathione
conjugation genes are reportedly decreased in aged Fischer
344 rats [65].
The Phase III hepatic pathway encompasses the trans-
porters onthe basolateral and apical sides of the hepatocytes,
which function to remove xenobiotics from the portal
blood and to excrete them or their metabolites in to bile
or blood, and includes the bile transporter P-gp [66–68].
The expression of hepatic transporters in response to drug
toxicity is poorly described in old age and will aﬀect biliary
excretion of drugs and their metabolites. There are few
human studies on Phase III hepatic metabolism in ageing. P-
gp expression is increased in aged Fischer-344 male, but this
isspeciﬁctotheliver[69].Asmallstudyofhealthyvolunteers
found decreased P-gp activity in the blood brain barrier of
ﬁve older healthy volunteers, age range 59–68 years [70]. It
must be noted that the wide geneticinterindividual variation
in expression of P-gp [71] may be further be confounded by
the increasing heterogeneity with age [67].Current Gerontology and Geriatrics Research 5
Ageing has been associated with decreased mRNA ex-
pression of organic anion-tran sporting polypeptide (Oatps)
includingOatp1a1,Oatp1b2,andOatp2b1,aswellasorganic
cation transporters (Octs) Oct1, and sodium/taurocholate-
cotransporting polypeptide in aged mice [53]. Furthermore,
themRNAexpression ofseveraleﬄuxtransporters including
Multidrug resistant protein (Mrp)-2, Mrp6 and Mrp3 have
been shown to be signiﬁcantly reduced in old age in mouse
livers [53]. However, what this means in terms of activity
and how it translates to humans still needs to be determined.
3.4. Mitochondrial Structure and Function in Old Age.
Changes in mitochondrial structure and function in old age
[72] alter the response to reactive oxygen species and cell
death pathways. It appears that malfunction and decrease
of biogenesis of mitochondria seem to exert some of the
most potent eﬀects on the organism [72]; however, the exact
mechanism still needs to be elucidated.
3.5. Glutathione in Old Age. Glutathione (GSH) has sev-
eral important functions including detoxiﬁcation of elec-
trophiles, maintenance of essential thiol status of proteins
and other molecules, scavenging of reactive oxygen species
(ROS), providing cysteine as well as modulation of critical
cellular processes such as DNA synthesis, microtubular-
related processes, and immune function [73, 74]. These
reactions are catalysed by the GSTs [74]. Hepatic GSH is
d e c r e a s e di na g e dr a t s[ 75, 76]a n di na g e dm i c e[ 77, 78].
Serum GSH and the levels of its associated enzymes are
d e c r e a s e di na g e i n gi nh u m a n s[ 79]. In rats, this age-related
decreasehasbeenshowntobefurtherexacerbatedbyethanol
consumption [80] which may be a problem in chronic
alcoholics.
3.6. Nrf-2 in Old Age. Nuclear factor E2-related factor 2
(Nrf-2) regulates the transcription of antioxidant genes
including genes for the Phase II conjugation enzymes (e.g.,
UGTs), glutathione homeostasis, stress response, and trans-
porter proteins through the antioxidant-responsive element.
Nrf-2 downregulation with ageing has been suggested as one
mechanistic explanation for reduced Phase II metabolism in
old age [81].
4.Implicationsof theAge-Related
AlterationsinHepaticPharmacology
and Toxicology
A decline in liver volume and liver blood ﬂow with ageing
may be a major component of age-related alterations in
the liver, leading to the fall in clearance of many of the
drugswhose pharmacokineticshave beenfound to bealtered
with age [9]. Hepatic clearance is inﬂuenced by substrate
delivery to the liver parenchymal cells and by the inherent
metabolic capacity of the hepatocytes. Therefore, any change
in the LSECs, including pseudocapillarisation, may alter
drug transfer from the blood to hepatocytes. Age-related
pseudocapillarisation has been shown to be associated with
impaired transfer of lipoproteins as well as with paracetamol
across the fenestrations [82, 83] as illustrated in Figure 2.
Changes in the inherent ability of the liver to detoxify
toxicmetabolites will lead to increased susceptibility to DILI.
This may be due to the age-related dysfunction and reduced
biogenesis of mitochondria [72], and/or the age-related
reduction in Phase II metabolism and reduced hepatic GSH
in old age [84], secondary to reduced transcriptional activity
of Nrf-2 [81].
Interestingly “themitochondrial hypothesis”implies that
the gradual accumulation of initially silent mitochondrial
injury which, when a critical threshold is reached, abruptly
triggers liver injury [85]. This could explain why DILI does
not aﬀect all individuals equally (duration of exposure is
not the same for all individuals), the delay in developing
DILI by weeks or months (accumulation of deﬁcits to
reach a threshold), and why increasing age is a risk factor
(due to duration of exposure or mitochondrial changes in
ageing) [86]. The role of these changes and their eﬀect on
paracetamol-induced liver injury will be discussed below.
5. Paracetamol-Induced LiverInjuryin Ageing
Paracetamol (oracetaminophen)isa p-aminophenol deriva-
tive which was discovered at the John Hopkins University
in 1877 [87]. Due to its safety proﬁle, paracetamol is
particularly useful in older adults; however, caution must be
taken because of its potential for toxicity [88]. Paracetamol
has the potential to cause liver damage and even liver failure
in overdose and now case reports are emerging of peo-
ple developing signiﬁcantly increased ALT concentrations
following therapeutic dosing [89], even in the absence of
risk factors [89, 90]. Paracetamol causes dose-dependent
hepatotoxicity through the metabolic bioactivation of the
parent drug to toxic metabolite [1].
5.1. Epidemiology. A recent systematic investigation by the
WHO Collaborating Centre for International Drug Moni-
toring reported that since 1969, paracetamol has been one
of the ﬁve most common drugs associated with fatalities
[91]. After 1990, there was a shift from halothane (immuno-
allergic DILI) being the most common drug associated with
a fatal outcome to paracetamol (dose-dependent DILI) [91,
92]. Table 3 shows selected reports of paracetamol-induced
hepatotoxicity deaths and transplants, with special reference
to those aged >60 years, in the United Kingdom, United
States, Canada, Malaysia, and Australia for the period 1989–
2010. In the United States, paracetamol is responsible for
approximately half of the cases of acute liver failure [1].
5.2. Hepatotoxicity. At therapeutic doses paracetamol meta-
bolised primarily in the liver to nontoxic metabolites via
Phase II metabolism (conjugation) with glucuronide and
sulphate,orcysteine [93].Asmall amountofdrugundergoes
Phase I CYP450-mediated N-hydroxylation to form N-
acetyl-p-amino-benzoquinone immine (NAPQI), a toxic
metabolite[93–95].Themostimportantisoformresponsible
for this CYP450-mediated metabolism is CYP2E1, but6 Current Gerontology and Geriatrics Research
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Figure 2: Age-related pseudocapillarisation of the liver sinusoid impairs the transfer of lipids (chylomicrons remnants) and paracetamol
across the fenestrated liver sinusoidal endothelial cells (LSECs). Adapted from Le Couteur et al., 2002 (20).
Table 3: Selected reports of paracetamol-related hepatotoxicity, deaths, and transplantsin the United States, Canada, United Kingdom,
Malaysia,and Australia for the period 1989–2010. Only studies that have included a sub grouping for “older adults”, deﬁned as those aged >
60 years, are included.
Source Approximate
population Size
Cases/million
population/year
%o fR e p o r t sf o rt h o s e
aged> 60 years
%o fR e p o r t s
unintentional Reference
Spontaneous ADR
reports, AUS
1990–2010
17–22.5 million 0.04 deaths 37.5% deaths NR
Pers. Comm. Graeme
Harris,
ACSOM,
24/8/2010
Ballarat Hospital
Records, AUS
2000–2003
0.2 million 240
hospitalisations 2.6% hospitalisations 4.7% [56]
Penang General
Hospital, Malaysia
2000–2002
Approx 1.3
million
42.3 cases of
poisoning 1.2% of poisoning cases 33.3% [57]
Calgary,
Canada1995–2004 1.1 million 140.2
hospitalisations 4.5% hospitalisations 13% [58]
US Transplant
Centres1998–2001
17 tertiary care
centres NR 6% ALFs
6.8% deaths 57% ALFs [59]
US 1990–2001 250 million 1.83 deaths 4% hospitalisations
14% deaths
23 %
hospitalisations
22% deaths
[60]
Cardiﬀ,U K
1989–2002
Approx 2.9
million
185 hospital
admissions
1.6 % of admissionsin
adults 60–69 years
1.8% of admissions in
adults >70 years
All intentional [61]
England and Wales
1993–1998 NR
15720 deaths, 13%
due to paracetamol
alone, 5.8% due to
paracetamol and
other drugs
11.5% deaths per million
males during 1993–1998
14.2% deaths per
million females
during 1993–1998
NR [62]
NR, not reported; US, United States; UK, United Kingdom; AUS, Australia; ADR, adverse drug reaction; ACSOM, Advisory Committee on the Safety of
Medicines; ALF, acute liver failure; APAP, paracetamol.
CYP3A4 and CYP1A2 are also involved [93]. Under normal
circumstances, NAPQI combines with sulphydryl groups in
hepatic glutathione and is neutralized [93, 96]. The major
conjugates, glucuronide and sulfate being more water-
soluble than the parent drug, are both eliminated from the
liver and blood mainly via the urine, with a small amount of
theglucuronideconjugateeliminatedviathebile[93,97,98].
Following ingestion of large amounts of paraceta-
mol, conjugation pathways become saturated resulting in
increased use of the CYP450 pathway, increased NAPQI
formation and increased depletion of hepatic glutathione
[97, 99]. The direct mechanism of paracetamol-induced
liver injury involves the formation of the toxic metabolite,
NAPQI, from paracetamol by the enzymes of the liver [100].Current Gerontology and Geriatrics Research 7
NAPQI can directly interact with macromolecules in the cell
causing protein dysfunction, lipid peroxidation, damage of
DNA, and oxidative stress [100]. Dysfunction of mitochon-
dria may also result thereby in interrupting energy produc-
tion and disrupting ionic gradients and intracellular calcium
stores to result in cell death and liver damage [100, 101].
The formation of reactive metabolites such as NAPQI is
animportantinitiatingfactorforDILI.Itistheinﬂammatory
immune response and the balance between the protective
and toxic signalling processes of the cells involved in this
response thatdeterminestheseverityandprogression ofliver
injury [102]. Holt and Ju (2006) suggest that hepatocyte
stress or death, as a result of the reactive metabolite induced
damage,causes the release of signals thatstimulate activation
of the innate immune cells of the liver [100]. KCs, natural
killer cells and neutrophils, are part of this response [103]
and are recruited and activated. These cells produce proin-
ﬂammatory cytokines and mediators such as tumor necrosis
factor (TNF)-α, interleukin (IL)-1β and interferon (IFN)-γ
[104–106]. Other mediators released by these immune cells
areprotectiveandanti-inﬂammatory suchasIL-10[106]and
IL-6 [107]. However, there is much disagreement between
the studies, and the exact role of each of the cell types
and mediators in DILI generally, as well as in paracetamol-
induced liver injury, has yet to be fully determined [100].
5.3. The Role of Kupﬀer Cells in Paracetamol Induced Hep-
atotoxicity. Paracetamol-induced hepatotoxicity has been
attributed in part to activation of KCs secondary to hepato-
cytedamageinitiatedbyNAPQI[108,109].Itisbelievedthat
Kupﬀer cell activation results in the release of a wide range
of proinﬂammatory mediators capable of causing further
hepatic injury [110]. However, there is controversial evi-
dence surrounding the role of KCs in paracetamol-induced
hepatotoxicity. The numbers of these F4/80 positive cells in
the liverare increased following paracetamol treatment [111,
112]. Yet, macrophage depletion has been shown to have a
role in both the protection [113] and potentiation of liver
injury [114]. Pretreatment of rats with macrophage inac-
tivators, such as gadolinium chloride and dextran sulfate,
has been shown to decrease hepatic injury from paracetamol
in rats [110, 115]. This was also observed in a mouse
model of hepatotoxicity [113, 114] with the protection being
ascribed to decreased formation of reactive oxygen and
nitrogen species [113]. The use of liposome-encapsulated
clodronate to deplete KCs from the liver [116]r e v e a l e da
hepatoprotective role in a mouse model of paracetamol-
induced liver injury [114]. Furthermore, the signiﬁcant
decrease in the levels of several cytokines and mediators,
including IL-6-, IL-10-, and IL-18-binding protein may
suggest that KCs mediate their beneﬁcial role via the release
of such soluble factors [114]. In support of this, it was
recently suggested that a disturbance in the T-helper (Th)-
1/Th-2 cytokine balance could play an important role in the
pathogenesis of paracetamol-induced liver injury [117].
5.4. The Role of LSECS and Microvasculature Disturbance
in Paracetamol Hepatotoxicity. It was recently suggested
that the hepatoprotective role of KCs may be mediated,
in part, via regulation of LSEC homeostasis and integrity
[118]. In mice, the early events occurring in the hepatic
microvasculature following paracetamol treatment include
LSEC injury, which was exhibited by the swelling of LSECs,
and the penetration of erythrocytes into the extra sinusoidal
space [119]. Interestingly, these ﬁndings precede hepatocyte
injury and suggestthattheLSECs area directand early target
during paracetamol hepatotoxicity [119, 120]. Furthermore,
the structural and functional changes in LSECs could
contribute to the initiation or progression of paracetamol-
induced liver injury [119]. Taken together, this indicates
that reduced sinusoidal perfusion and increased Kupﬀer cell
activity participate in the developmentof liver injury elicited
by paracetamol [119].
5.5. The Eﬀect of Ageing on Susceptibility to Paracetamol-
Induced Liver Injury. Risk factors for paracetamol hepa-
totoxicity include malnutrition which results in depletion
of glutathione [121], chronic alcohol consumption, which
acts to both reduce glutathione stores and induce CYP2E1
[122], and concurrent use of CYP-inducing drugs such as
Isoniazid [123]. Inﬂammation as a result of bacterial or viral
infection has also been identiﬁed as a risk factor for parac-
etamol hepatotoxicity [124] along with liver disease [125].
Interestingly,polymorphisms intheCYP2E1enzymecausing
altered acetylation status have been shown to be a factor
inﬂuencing isoniazid hepatotoxicity [126, 127]. Conceivably,
this may also be applicable to paracetamol with those
individuals with a “rapid acetylator” phenotype may have
accelerated production of the hepatotoxic NAPQI, however
thisneedstobesubstantiatedfurther. Furthermore,theeﬀect
of age on these risk factors is not fully understood. Figure 3
describes the risk factors for paracetamol hepatotoxicity and
the eﬀect of age as a modiﬁer of the risk factor. Increasing
age is associated with increased time to presentation [128],
resulting in poorer outcome. Interestingly, in rats the risk of
hepatotoxicity from paracetamol decreases with increasing
age [129]. It also must be acknowledged that elevated liver
enzymes after exposure to paracetamol have occurred in
adults who have none of the reported risk factors for
paracetamol toxicity [89, 130].
The risk of hepatotoxicity from therapeutic doses of
paracetamol in older people is not well deﬁned. Older frail
hospital in patients taking therapeutic paracetamol for ﬁve
daysdonot havean increased risk ofraised ALTcompared to
younger patient, although the clinical implications of such
ﬁndings are not clear [131]. In people aged ≥ 65 years,
the clinical increased risk of paracetamol hepatotoxicity is
likely related to dosing that does not account for decreased
liver volume with age, and to frailty and malnutrition [8].
Ageing and frailty are associated with a loss of reserves
and increased state of vulnerability [132]. Therefore it is
likely that the older frail patient will be at increased risk
of DILI from therapeutic doses of medications. Changes in
drug clearance in old age aﬀect the formation and clearance
of the toxic metabolites and therefore the susceptibility to
DILI [67]. Interestingly one determinant of the variability in
susceptibility to hepatotoxicity appears to be inﬂammatory8 Current Gerontology and Geriatrics Research
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Figure 3: The eﬀect of age on risk factors for paracetamol-induced hepatotoxicity and the potential mechanism through which they may
act.
stress [1]. Subclinical chronic activation of the immune
system in older people [133] is likely to result in decreased
response to injury. Figure 4 summarises the paracetamol
hepatotoxicity pathway and identiﬁes potential parts of the
pathway at which ageing may act to increase or decrease
the susceptibility to toxicity. However, this is likely to vary
between individuals.
5.6. Detection and Management of Paracetamol-Induced Liver
Injury. Clinically, paracetamol overdose is associated with
three main stages. The ﬁrst lasts for approximately 24 hours
and involves nonspeciﬁc gastrointestinal symptoms such
as nausea, vomiting and abdominal pain with minimal
elevation in serum liver enzyme concentrations. The second
stage, from 24–72 hours, involves most notably the elevation
of serum aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) concentrations released from dam-
aged hepatocytes [134–136]. Serum ALT and total bilirubin
are themost commonbiomarkers used todetect and manage
hepatocellular injury [137]. Serum ALT is more liver speciﬁc
than AST and is a very sensitive detector of hepatocellular
necrosis; however, it cannot distinguish DILI from necrosis
resulting from other causes such as viral hepatitis, alcohol
consumption, or other unexplainable reasons [137–139].
In patients with ap r i o r ielevated transaminases, this is
further complicated due to the lack of guidelines as to what
contributes a signiﬁcant increase [138]. In older people,
reduced liver size may mean transaminases do not increase
as substantially as for younger people [29, 140].
Serum paracetamol concentrations are used to guide
treatment in overdose [142]. However, there is still limited
evidence on the relationship between therapeutic serum
paracetamol concentrations and risk of hepatotoxicity, as in
older adults high serum concentrations are not necessarily
associated with increased ALT levels [131]. The third stage of
clinical paracetamol overdose develops in the next 24 hours,
with the symptoms and outcome varying from full recovery
to death depending on the severity of the liver damage [101].
Liver biopsy reveals a centrilobularnecrosis, with periportal
sparing and little or no inﬂammatory reaction [93, 134]. In
severe cases, acute renal failure may occur [93]. Pharmaco-
metabolonomics may help predict individuals at risk of
paracetamol hepatotoxicity in the future [143].
5.7. Management and Treatment of Paracetamol-Induced
Liver Injury. Early intervention is essential, as the aim of
treatment is to prevent progression to acute liver failure.
Paracetamol remains the only hepatotoxin to have eﬀective
pharmacotherapy, N-acetylcysteine (NAC), based on well-
established nomograms [142]. The beneﬁt of NAC extends
those who have developed fulminant hepatic failure [144].
In older people, increased age is associated with increased
time to presentation which may be explained in part by the
higher proportion of accidental overdose in older patients
[128]. By the time older adults present, NAC may no longer
be beneﬁcial despite being indicated for late presenters (10–
24 hours after overdose) [144].
Adjunctive therapy such as corticosteroids or ursodeoxy-
cholic acid is based on anecdotal evidence. The pharma-
cotherapy ofend-stage liverdisease (diuretics,beta-blockers)
is the same as for other causes of liver disease [144]; however,
this is not well described in ageing [86]. Older people do
however suﬀer more ADRs to beta blockers and diuretics
[145]. Studies in mice have indicated the usefulness of
cimetidine both alone (two doses at 2 and 6hours post
paracetamol) and in combination therapy with NAC to
reduce ALT/AST concentrations and increase hepatic GSH
following paracetamol overdose [146]. Cimetidine may have
limited use in hospitalised overdose patients with no eﬀect
on ALT/AST being observed if the cimetidine was given after
8 hours after overdose [147]. Additionally, cimetidine has
anticholinergic side eﬀects in older adults, which are well
known to be associated with poorer functional outcomes
[148, 149], further limiting the use of this adjuvant in older
patients in clinical care.
6. FutureDirections
A number of antioxidants have shown promise in protect-
ing against paracetamol-inducedliver injury. These includeCurrent Gerontology and Geriatrics Research 9
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Saturation ofconjugation pathways results in increased use of the CYP450 pathway, increased NAPQI formation,and increased depletion of
hepatic glutathione. NAPQI can cause injury through direct cell stress, direct mitochondrial inhibition, or through immune reactions.
Initial injury leads to mitochondrial dysfunction leading to either apoptosis of damaged cells, or necrosis with recovery, chronic
liver injury or actual liver failure, and death as potential outcomes. Additionally, necrosis can stimulate the inﬂammatory response
leading to cytokine release and further potentiation of the immune reaction. Ageing can act at multiple parts of the pathway to either
increase (↑)o rd e c r e a s e( ↓) susceptibility to hepatotoxicity. It must be noted, however, that this is likely to vary between individuals.
The eﬀect of ageing on Phase III transporters is somewhat unknown (?) in humans. Picture adapted from Russmann et.al., 2009
[141].
silymarin [150], resveratrol [151], Ukrain [152], Garcinia
kola seed extract [153], Ginkgo biloba extract [154], L-
carnitine [155] and oleanic acid [156]. All propose to protect
from hepatotoxicity through reduction of oxidative stress
mechanisms. However, it must be noted that while these
compounds have shown promise in the laboratory setting in
animal models, they all suﬀer the limitation of being given
prior to paracetamol overdose. Interestingly, prostagland E2
g i v e ne i t h e rb e f o r eo r2h o u r sa f t e rp a r a c e t a m o lo v e r d o s e
showed signiﬁcant hepatoprotective eﬀects in mice [157].
However, their eﬃcacy as a therapy postparacetamol treat-
ment and in humans in the clinical setting still needs to be
substantiated.
7.Conclusion
Optimal pharmacotherapy is determined when the pharma-
cokinetics and pharmacodynamics of the drug are under-
stood.However,theage-related changesin pharmacokinetics
and pharmacodynamics aswell as the increased interindivid-
ual variation mean optimal dose selection is a challenge for
prescribing in older adults. Paracetamol remains the ﬁrst-
line analgesic of choice for nonmalignant pain; however,
dose reduction is mandated for frail older adults despite the
pharmacokinetic and pharmacodynamicevidence for such a
dose reduction being lacking. Animal studies have indicated
a reduction in toxicity in old age, and this may possibly be
the same for older frail adults. Understanding how ageing
and frailty aﬀect changes in drug clearance and toxicity will
improve utilisation of thisvaluable analgesic and many other
medicines by older adults.
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